Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 3:8:218.
doi: 10.3389/fcell.2020.00218. eCollection 2020.

An Appraisal on the Value of Using Nutraceutical Based Senolytics and Senostatics in Aging

Affiliations
Review

An Appraisal on the Value of Using Nutraceutical Based Senolytics and Senostatics in Aging

Amanpreet Kaur et al. Front Cell Dev Biol. .

Abstract

The average human life expectancy has increased globally, and continues to rise, owing to the substantive progress made in healthcare, medicine, sanitation, housing and education. This ultimately enriches society with a greater proportion of elderly people. Sustaining a healthy aged population is key to diminish the societal and economic impact of age-related infirmities. This is especially challenging because tissue function, and thus wellbeing, naturally progressively decline as humans age. With age increasing the risk of developing diseases, one of the therapeutic options is to interfere with the molecular and cellular pathways involved in age-related tissue dysfunction, which is in part caused by the accumulation of senescent cells. One strategy to prevent this could be using drugs that selectively kill these cells (senolytics). In parallel, some compounds have been identified that prevent or slow down the progression of senescence or some of its features (senostatics). Senolytic and senostatic therapies have been shown to be efficient in vivo, but they also have unwanted dose-dependent side effects, including toxicity. Important advances might be made using bioactive compounds from plants and foods (nutraceuticals) if, as is proposed, they offer similar effectiveness with fewer side effects. The focus of this review is on the use of nutraceuticals in interfering with cellular senescence.

Keywords: aging; nutraceuticals; senescence; senolytics; senostatics.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Characteristics of Cellular Senescence. Senescent cells will undergo multiple changes, with morphology becoming larger and flatter, an increased expression of SA- β -Gal activity, loss of nuclear membrane integrity, cease in cell proliferation and the production of SASP, including an increased expression of matrix metalloproteases (MMPs), cytokines and chemokines.
FIGURE 2
FIGURE 2
Chemical structures of Epigallocatchin gallate (EGCG), Fisetin, Resveratrol, Hydroxytyrosol (HT) and Oleuropein aglycone (OLE). These compounds consist of either phenolic of polyphenolic alcohol groups (National Center for Biotechnology Information, 2019a,b,c,d,e).

Similar articles

Cited by

References

    1. Aird K., Zhang R. (2012). Detection of senescence-associated heterochromatin foci (SAHF). Methods Mol. Biol. 965 185–196. 10.1007/978-1-62703-239-1_12 - DOI - PMC - PubMed
    1. Alcorta D., Xiong Y., Phelps D., Hannon G., Beach D., Barrett J. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 93 13742–13747. 10.1073/pnas.93.24.13742 - DOI - PMC - PubMed
    1. Althubiti M., Rada M., Samuel J., Escorsa J., Najeeb H., Lee K., et al. (2016). BTK modulates p53 activity to enhance apoptotic and senescent responses. Cancer Res. 76 5405–5414. 10.1158/0008-5472.CAN-16-0690 - DOI - PubMed
    1. Astle M., Hannan K., Ng P., Lee R., George A., Hsu A., et al. (2011). AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 31 1949–1962. 10.1038/onc.2011.394 - DOI - PMC - PubMed
    1. Bailey C. (2017). Metformin: historical overview. Diabetologia 60 1566–1576. 10.1007/s00125-017-4318-z - DOI - PubMed

LinkOut - more resources